BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28448462)

  • 1. Targeting the ATR-CHK1 Axis in Cancer Therapy.
    Rundle S; Bradbury A; Drew Y; Curtin NJ
    Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28448462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress towards a clinically-successful ATR inhibitor for cancer therapy.
    Barnieh FM; Loadman PM; Falconer RA
    Curr Res Pharmacol Drug Discov; 2021; 2():100017. PubMed ID: 34909652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.
    Manic G; Obrist F; Sistigu A; Vitale I
    Mol Cell Oncol; 2015; 2(4):e1012976. PubMed ID: 27308506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New horizons in lung cancer management through ATR/CHK1 pathway modulation.
    Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
    Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
    Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
    [No Abstract]   [Full Text] [Related]  

  • 10. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
    Boudny M; Trbusek M
    Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
    Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
    Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
    Ngoi NYL; Peng G; Yap TA
    Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
    Mei L; Zhang J; He K; Zhang J
    J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
    Bradbury A; Hall S; Curtin N; Drew Y
    Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
    Shaik A; Bhakuni R; Kirubakaran S
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Kuca K
    Curr Cancer Drug Targets; 2016; 16(3):200-8. PubMed ID: 26882028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.